198 related articles for article (PubMed ID: 11365359)
21. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Nokta M; Rossero R; Loesch K; Pollard RB
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
[TBL] [Abstract][Full Text] [Related]
22. Principles of treating HIV.
Johnson D
S Afr Med J; 2000 Mar; 90(3):227-30. PubMed ID: 10853393
[No Abstract] [Full Text] [Related]
23. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
24. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Sanne I; Smego RA; Mendelow BV
Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
[TBL] [Abstract][Full Text] [Related]
25. New data intensifies interest in hydroxyurea.
Santiago LG
GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
[TBL] [Abstract][Full Text] [Related]
26. Some competition for 1592.
GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
[TBL] [Abstract][Full Text] [Related]
27. Anti-HIV therapy update.
Proj Inf Perspect; 2001 Mar; (32):4-6. PubMed ID: 11682776
[No Abstract] [Full Text] [Related]
28. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
Murphy MJ
Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
[TBL] [Abstract][Full Text] [Related]
29. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
Delaugerre C
Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
[No Abstract] [Full Text] [Related]
30. Anti-HIV agents. Long-term use of hydroxyurea.
TreatmentUpdate; 2000 Sep; 12(6):2-3. PubMed ID: 12132459
[No Abstract] [Full Text] [Related]
31. French investigators warn of LPV/TDF/ddI interaction.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
[No Abstract] [Full Text] [Related]
32. Antiviral update.
PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
[TBL] [Abstract][Full Text] [Related]
33. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
Moore RD; Wong WM; Keruly JC; McArthur JC
AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
[TBL] [Abstract][Full Text] [Related]
34. Another take on when to start and how to succeed.
Friedland GH
AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
[No Abstract] [Full Text] [Related]
35. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
[TBL] [Abstract][Full Text] [Related]
37. [Hydroxyurea and HIV infection].
Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
[TBL] [Abstract][Full Text] [Related]
38. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
[TBL] [Abstract][Full Text] [Related]
39. Dethroning AZT.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
[TBL] [Abstract][Full Text] [Related]
40. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
